Medscape is available in 5 Language Editions – Choose your Edition here.


Charcot-Marie-Tooth and Other Hereditary Motor and Sensory Neuropathies

  • Author: Timothy C Parsons, MD; Chief Editor: Nicholas Lorenzo, MD, MHA, CPE  more...
Updated: Dec 14, 2015


Slowly progressive distal weakness, muscle atrophy, and sensory loss due to an inherited peripheral neuropathy was described independently in 1886 by Charcot and Marie in France and by Tooth in England.[1, 2] A few years later, Dejerine and Sottas recognized and described a more severe, infantile form of inherited neuropathy.[3]

As more heterogeneity and overlap in clinical appearance, pathological features, and forms of inheritance were recognized in the following decades, an improved classification system was needed to avoid confusion. Starting in the 1950s, the clinical use of nerve conduction studies combined with pathological information allowed patients to be divided into 2 major groups.

  • Group 1 was characterized by slow nerve conduction velocities and evidence of hypertrophic demyelinating neuropathy.
  • Group 2 was characterized by relatively normal nerve conduction velocities and axonal degeneration.

Most of the families demonstrated autosomal dominant inheritance, and affected relatives in each family could all be categorized in the same group.[4, 5, 6]

In 1975, Dyck expanded the classification system of what was now known as hereditary motor and sensory neuropathy (HMSN) to include forms with additional features.[7]

  • HMSN types 1A and 1B (dominantly inherited hypertrophic demyelinating neuropathies)
  • HMSN type 2 (dominantly inherited neuronal neuropathies)
  • HMSN type 3 (hypertrophic neuropathy of infancy [Dejerine-Sottas])
  • HMSN type 4 (hypertrophic neuropathy [Refsum] associated with phytanic acid excess)
  • HMSN type 5 (associated with spastic paraplegia)
  • HMSN type 6 (with optic atrophy)
  • HMSN type 7 (with retinitis pigmentosa)

In the 1980s it became clear that this revised classification system, based on clinical and electrophysiologic characteristics, was inadequate to describe the genetic heterogeneity within each of these categories. Linkage studies revealed Charcot-Marie-Tooth type 1 loci on both chromosome 1[8] and chromosome 17[9] , and X-linked and recessively inherited forms were increasingly recognized.

In 1991, 2 groups showed that the most common form of CMT1, known as CMT1A, was associated with a duplication within chromosome 17p11.2.[10, 11] This duplication is believed to be in the peripheral myelin protein 22kD (PMP22) gene, and overexpression of the gene product appears to be causative, since a gene dosage effect has been demonstrated.[12] It is estimated that this duplication is responsible for about 70% of CMT1 cases[13] and the vast majority of CMT1A cases, with rare exceptions such as partial 17p trisomy.[12, 14]

Other Charcot-Marie-Tooth genes were discovered in the 1990s. The second most common form of CMT1 (CMT1B) and some cases of Déjerine-Sottas syndrome were found to be associated with mutations in the myelin protein zero (MPZ) gene on chromosome 1.[15, 16, 17] The most common form of CMTX (CMTX1), was found to be due to mutations in the gap junction protein beta 1/connexin 32 (Cx32) on chromosome Xq13.1.[18] Interestingly, hereditary neuropathy with liability to pressure palsies (HNPP) was found to be associated with a deletion in the PMP22 gene[19] , but this syndrome will not be reviewed here.

The difficulty classifying Charcot-Marie-Tooth subtypes is made more evident by the fact that mutations of each of these genes have been associated with multiple, overlapping phenotypes. For instance, myelin protein zero mutations are associated CMT1B, Déjerine-Sottas syndrome, and the axonal CMT2 phenotype.[20, 21, 22] Déjerine-Sottas syndrome has been associated with mutations or deletions in PMP22, myelin protein zero, and early growth response 2 (EGR2) genes.[15, 23, 24]

In addition, the boundaries between even the major types of CMT are not always as clear as the original series suggested. In the mid 1970s, Bradley, Davis, and Madrid performed a similar study to those performed by Dyck and Lambert, Thomas and Calne, and Buchthal and Behse, and proposed a CMT classification that included an intermediate group characterized by median motor nerve conduction velocities of 25-45 m/sec and intermediate pathological changes.[25, 26, 27] A study performed by Brust, Lovelace, and Devi suggested a bimodality in nerve conduction velocities among type 1 patients, again raising the possibility of an intermediate form[28] , but these were considered exceptions and were never incorporated into the major classification systems. In 1985, a large kinship with an intermediate form was described.

In 1998, sequencing of the PMP22 and MPZ genes in this kinship did not reveal mutations, underscoring that it is a distinct entity.[29, 30] Several associated mutations have been discovered since, and as with other forms of CMT, these studies have demonstrated genetic heterogeneity.

Given what is now known about clinical and genetic heterogeneity, a system that takes both clinical and genetic characteristics into account is not possible. This review will use the following system:

  • CMT1 is a dominantly inherited, hypertrophic, predominantly demyelinating form.
  • CMT2 is a dominantly inherited predominantly axonal form.
  • Dejerine-Sottas is a severe form with onset in infancy.
  • CMTX is inherited in an X-linked manner.
  • CMT4 includes the various demyelinating autosomal recessive forms of Charcot-Marie-Tooth disease.



The extra PMP22 gene copy within the 1.5 mB duplication on chromosome 17 is believed to cause most cases.[12] PMP22 is a 160 amino acid integral membrane protein that is expressed at high levels in myelinating Schwann cells, localizing to compact myelin and making up 2–5% of total myelin protein.[31, 32] PMP22 expression in CMT1A nerve biopsies is increased[33] , but the process by which protein overexpression actually causes the Charcot-Marie-Tooth phenotype remains unclear.

Abnormal expression of PMP22 seems to alter Schwann cell growth and differentiation both in vivo and in vitro, and may impair the ability of the Schwann cell to maintain normal myelin stability and turnover. A putative interaction between PMP22 and MPZ could play a role in maintaining myelin compaction and stability, and an imbalance in one could explain why changes in expression in either gene can lead to the clinically and pathologically indistinguishable CMT1A and CMT1B phenotypes.[34]

Despite the evidence of demyelination found on pathological and electrophysiological studies and the more recent implication of myelin proteins, the signs and symptoms of weakness and sensory loss are likely the result of axonal degeneration rather than demyelination. Anatomical evidence of progressive length-dependent axonal loss following demyelination in CMT1 exists.[35] Children with CMT1A have slow nerve conduction velocities in the first years of life, generally preceding the development of signs and symptoms.[36] Krajewski and colleagues demonstrated that compound motor action potential amplitudes correlate best with weakness in CMT1A rather than nerve conduction velocities.[37]

In vivo studies of CMT1A patients have demonstrated altered axonal excitability, in the form of elevated stimulation thresholds and a markedly abnormal threshold electrotonus. These findings suggested that demyelination causes exposure of fast K+ channels, which are normally sequestered under the myelin.[38]


Myelin protein zero is an integral type I membrane protein, and is the most abundant structural protein of compact peripheral nerve myelin.[39, 15]

More than 80 mutations in myelin protein zero have been described. Most are associated with the typical CMT1B phenotype, but correlations have been found with other clinical phenotypes including CMT2, Dejerine Sottas syndrome, and congenital hypomyelination neuropathy.[40, 41]

Predominantly axonal and predominantly demyelinating forms appear to be due to different mutations in the same gene. Mutations that introduce a charged amino acid, removed or added a cysteine residue, or altered an evolutionarily conserved amino acid alter the tertiary structure of the MPZ protein as a result and lead to the more severe early onset phenotype. As with diseases of PMP22 expression, the mechanism for either demyelinating or axonal forms remains unclear, but may be due to impaired myelin-axon interaction.[42, 43, 44]


CMTX is caused by mutations in connexin32/Gap Junction Beta 1 (Cx32 or GJB1), which maps to chromosome Xq13. Connexins assemble to form intercellular gap junctions, which allow the diffusion of ions and small molecules across apposed cell membranes. Connexin 32 is expressed in many tissues, but is localized in the myelin sheath of large diameter fibers near the nodes of Ranvier.[18, 45]

Axonal and demyelinating changes are mixed in CMTX. Men are clinically and electrophysiologically more severely affected than affected women. Interestingly, nerve conduction velocities in affected women can vary markedly within the same limb, in contrast to men whose conduction velocities tend to resemble the diffusely slow velocities seen in CMT1. This may be partly explained by X-inactivation of Schwann cell precursors during development. The mechanisms by which different Cx32 mutations cause CMT1X are not fully understood. Phenotype-genotype correlations in CMT1X will be difficult to establish because of phenotypic variability both within and between kindreds.[46, 47, 48]


The most common mutation responsible for CMT2 has been found in the mitochondrial GTPase mitofusin 2 (MFN2) gene.[49] This is referred to as CMT2A.

MFN2 is a dynamin family GTPase that spans the outer mitochondrial membrane and is believed to primarily be involved in mitochondrial docking, tethering, and fusion. Recent data were supportive of a mitochondrial trafficking insult as a possible mechanism of length-dependent axonal neuropathy.[50, 51]


The causes of CMT4 are diverse and very rare and will not be reviewed here.





CMT is the most common inherited neuromuscular disorder. Estimates of the frequency of Charcot-Marie-Tooth disease vary widely. In 1974, Skre and colleagues reported a prevalence of 1 case per 2,500 individuals. A worldwide meta-analysis estimated a prevalence of 1 per 10,000 individuals, and a prevalence of 10.8 per 100,000 was found in western Japan.[52, 53]

Charcot-Marie-Tooth disease type 1 accounts for about two thirds of CMT cases. Of these, 70% are due to duplications in PMP22. Duplications in PMP22 therefore account for roughly half of all combined CMT subtypes.[13, 54] CMT1B makes up about 5% of CMT1 and about 1.6% of all CMT cases.[54, 55]

Charcot-Marie-Tooth disease type 2 accounts for about 22% of CMT cases.[54] CMT2A (MFN2 mutation) has been estimated to account for 11-23% of all CMT2 cases.[56]

Charcot-Marie-Tooth disease type X accounts for about 16% of CMT cases.[54] CMTX1 (Cx32 mutation) accounts for most CMTX cases and may be the second most common cause of CMT overall, at 7-20%.[42, 43]


Most people with CMT have a normal life expectancy, the exceptions being patients with respiratory involvement or severe disability. Disability varies greatly both between and within families, and can range from asymptomatic with minimal examination findings to severe. Marked differences in clinical severity have even been reported in monozygotic twins with CMT1A (despite similar nerve conduction velocities)[57] and myelin protein zero mutations[58] .

A 2001 study showed that 44% of CMT1A patients were significantly disabled, and 18% were depressed. It was estimated that CMT1 patients suffer emotional stress similar to patients with stroke and comparable disability.[59]

CMT is nearly always slowly progressive. A longitudinal study showed steady progression in nerve conduction velocity and disability, and severity could be predicted based on nerve conduction velocity abnormalities in childhood.[60] Killian and colleagues studied nerve conduction velocities and neurologic examinations in 8 members of a single family over 22 years and found minimal progression of disability.[61] Another study of 43 patients with CMT2 over 5 years documented slow progression of weakness and disability, and most patients remained ambulatory.[62]

As CMT is relatively common, it can occur with other inherited or acquired neuromuscular conditions. If progression accelerates, these possibilities should be pursued.[63]


No racial predilection is recognized in the common forms of CMT. Rare, recessively inherited forms (CMT4) cluster in particular ethnic groups.


As expected, CMTX affects males earlier, more frequently, and more severely than females. Other forms of CMT do not show predilection for either sex.


Onset is usually in childhood. Thomas and colleagues found that 75% of patients with CMT1A developed clinical evidence of disease before age 10, and 85% before age 20.[64] Some patients experience very slow progression of mild, lifelong symptoms, and may seek medical attention only late in life.

There are patients and families in which CMT has a late onset, as late as the fifth or sixth decade in some MPZ mutations, and even as late as the seventh decade in CMT2.[41, 65]

Contributor Information and Disclosures

Timothy C Parsons, MD Fellow in EMG and Neuromuscular Disease, Department of Neurology, Columbia University Medical Center, New York

Timothy C Parsons, MD is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.


Thomas H Brannagan III, MD Associate Professor of Clinical Neurology and Director, Peripheral Neuropathy Center, Columbia University, College of Physicians and Surgeons; Co-Director, EMG Laboratory, New York-Presbyterian Hospital, Columbia Campus, New York

Thomas H Brannagan III, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, Peripheral Nerve Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Neil A Busis, MD Chief of Neurology and Director of Neurodagnostic Laboratory, UPMC Shadyside; Clinical Professor of Neurology and Director of Community Neurology, Department of Neurology, University of Pittsburgh Physicians

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Chief Editor

Nicholas Lorenzo, MD, MHA, CPE Founding Editor-in-Chief, eMedicine Neurology; Founder and CEO/CMO, PHLT Consultants; Chief Medical Officer, MeMD Inc

Nicholas Lorenzo, MD, MHA, CPE is a member of the following medical societies: Alpha Omega Alpha, American Association for Physician Leadership, American Academy of Neurology

Disclosure: Nothing to disclose.

Additional Contributors

Dianna Quan, MD Professor of Neurology, Director of Electromyography Laboratory, University of Colorado School of Medicine

Dianna Quan, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Neurological Association

Disclosure: Nothing to disclose.

  1. Charcot JM. Sur une forme particulaire d'atrophie musculaire progressive souvent familial debutant par les pieds et les jambes et atteingnant plus tard les mains. Rev Med. 1886. 6:97-138.

  2. Tooth HH. The peroneal type of progressive muscular atrophy. London: Lewis. 1886.

  3. Dejerine H, Sottas J. Sur la nevrite interstitielle, hypertrophique et progressive de l'enfance. CR Soc Biol (Paris). 1893. 45:63-96.

  4. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. I. Neurologic, genetic, and electrophysiologic findings in hereditary polyneuropathies. Arch Neurol. 1968 Jun. 18(6):603-18. [Medline].

  5. Thomas PK, Calne DB. Motor nerve conduction velocity in peroneal muscular atrophy: evidence for genetic heterogeneity. J Neurol Neurosurg Psychiatry. 1974 Jan. 37(1):68-75. [Medline].

  6. Buchthal F, Behse F. Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography. Brain. 1977 Mar. 100 Pt 1:41-66. [Medline].

  7. Dyck PJ. Inherited neuronal degeneration and atrophy affecting peripheral motor, sensory and autonomic neurons. Dyck PJ, Thomas PK, and Lambert EH. Peripheral Neuropathy. 1. Philadelphia: Saunders; 1975. 2: 825-867.

  8. Bird TD, Ott J, Giblett ER. Evidence for linkage of Charcot-Marie-Tooth neuropathy to the Duffy locus on chromosome 1. Am J Hum Genet. 1982 May. 34(3):388-94. [Medline].

  9. Vance JM, Nicholson GA, Yamaoka LH, Stajich J, Stewart CS, Speer MC, et al. Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol. 1989 May. 104(2):186-9. [Medline].

  10. Lupski JR, de Oca-Luna RM, Slaugenhaupt S. DNA duplication associated with Charcot-Marie-Tooth Disease Type 1A. Cell. 1991. 66:219-32.

  11. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). Neuromuscul Disord. 1991. 1:93-7.

  12. Lupski JR, Wise CA, Kuwano A, Pentao L, Parke JT, Glaze DG. Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A. Nat Genet. 1992 Apr. 1(1):29-33. [Medline].

  13. Wise CA, Garcia CA, Davis SN, Heju Z, Pentao L, Patel PI. Molecular analyses of unrelated Charcot-Marie-Tooth (CMT) disease patients suggest a high frequency of the CMTIA duplication. Am J Hum Genet. 1993 Oct. 53(4):853-63. [Medline].

  14. Fernandez-Torre JL, Otero B, Alvarez V, Hernando I, Fernandez-Toral J. De novo partial duplication of 17p associated with Charcot-Marie-Tooth disease type 1A. J Neurol Neurosurg Psychiatry. 2001. 70:703-4.

  15. Hayasaka K, Himoro M, Sato W, et al. CMT neuropathy 1B is associated with mutations of the myelin P0 gene. Nat Genet. 1993. 5:31-4.

  16. Kulkens T, Bolhuis PA, Wolterman RA, Kemp S, te Nijenhuis S, Valentijn LJ. Deletion of the serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-Marie-Tooth disease type 1B. Nat Genet. 1993 Sep. 5(1):35-9. [Medline].

  17. Su Y, Brooks DG, Li L, Lepercq J, Trofatter JA, Ravetch JV, et al. Myelin protein zero gene mutated in Charcot-Marie-tooth type 1B patients. Proc Natl Acad Sci U S A. 1993 Nov 15. 90(22):10856-60. [Medline].

  18. Bergoffen J, Scherer SS, Wang S, Scott MO, Bone LJ, Paul DL. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science. 1993 Dec 24. 262(5142):2039-42. [Medline].

  19. Chance PF, Alderson MK, Leppig KA, Lensch MW, Matsunami N, Smith B. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell. 1993 Jan 15. 72(1):143-51. [Medline].

  20. Warner LE, Hilz MJ, Appel SH, et al. Clinical phenotypes of different MPZ (P-O) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron. 1996. 17:451-60.

  21. Marrosu MG, Vaccargiu S, Marrosu G, Vannelli A, Cianchetti C, Muntoni F. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology. 1998 May. 50(5):1397-401. [Medline].

  22. Tazir M, Bellatache M, Nouioua S, Vallat JM. Autosomal recessive Charcot-Marie-Tooth disease: from genes to phenotypes. J Peripher Nerv Syst. 2013 Jun. 18(2):113-29. [Medline].

  23. Numakura C, Shirahata E, Yamashita S, et al. Screening of the early growth response 2 gene in Japanese patients with Charcot-Marie-Tooth disease type 1. J Neurol Sci. 2003. 210:61- 64.

  24. Roa BB, Dyck PJ, Marks HG, Chance PF, Lupski JR. Dejerine -Sottas syndrome associated with point mutation in the peripheral myelin protein 22 (PMP22) gene. Nat Genet. 1993. 5:269- 73.

  25. Bradley WG, Madrid R, and Davis, CJF . The peroneal muscular atrophy syndrome. Clinical, genetic, electrophysiological, and nerve biopsy studies. III. Clinical, electrophysiological, and pathological correlations. J Neurol Sci. 1977. 32:123-36.

  26. Madrid R, Bradley WG, and Davis, CJF. The peroneal muscular atrophy syndrome. Clinical, genetic, electrophysiological, and nerve biopsy studies. II. Observations on pathological changes in sural nerve biopsies. J Neurol Sci. 1977. 32:91-122.

  27. Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Genet Hum. 1978 Dec. 26(4):311-49. [Medline].

  28. Brust JCM, Lovelace RE, and Devi S. Clinical and electrodiagnostic features of Charcot-Marie-Tooth syndrome. Acta Neurologica Scandinavica. 1978. 58:Supplement 68: 1-42.

  29. Rossi A, Paradiso C, Cioni R, Rizzuto N, Guazzi G. Charcot-Marie-Tooth disease: study of a large kinship with an intermediate form. J Neurol. 1985. 232(2):91-8. [Medline].

  30. Villanova M, Timmerman V, De Jonghe P, Malandrini A, Rizzuto N, Van Broeckhoven C, et al. Charcot-Marie-Tooth disease: an intermediate form. Neuromuscul Disord. 1998 Aug. 8(6):392-3. [Medline].

  31. Hai M, Bidichandani SI, Patel PI. Identification of a positive regulatory element in the myelin-specific promoter of the PMP22 gene. J Neurosci Res. 2001 Sep 15. 65(6):508-19. [Medline].

  32. Snipes GJ, Suter U, Welcher A, Shooter E. Characterization of a Novel Peripheral Nervous System Myelin Protein (PMP22/SR13). J Cell Bio. 1992. 117:225-238.

  33. Vallat JM, Sindou P, Preux PM, Tabaraud F, Milor AM, Couratier P. Ultrastructural PMP22 expression in inherited demyelinating neuropathies. Ann Neurol. 1996 Jun. 39(6):813-7. [Medline].

  34. Müller HW. New vistas on the pathomechanism of Charcot-Marie-Tooth and related peripheral neuropathies. Ann N Y Acad Sci. 1999 Sep 14. 883:152-9. [Medline].

  35. Gabreëls-Festen AA, Joosten EM, Gabreëls FJ, Jennekens FG, Janssen-van Kempen TW. Early morphological features in dominantly inherited demyelinating motor and sensory neuropathy (HMSN type I). J Neurol Sci. 1992 Feb. 107(2):145-54. [Medline].

  36. García A, Combarros O, Calleja J, Berciano J. Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic study. Neurology. 1998 Apr. 50(4):1061-7. [Medline].

  37. Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain. 2000 Jul. 123 ( Pt 7):1516-27. [Medline].

  38. Nodera H, Bostock H, Kuwabara S, Sakamoto T, Asanuma K, Jia-Ying S, et al. Nerve excitability properties in Charcot-Marie-Tooth disease type 1A. Brain. 2004 Jan. 127:203-11. [Medline].

  39. Giese KP, Martini R, et al. Mouse PO Gene Disruption Leads to Hypomyelination, Abnormal Expression of Recognition Molecules, and Degeneration of Myelin and Axons. Cell. 1991. 71:565-576.

  40. Nelis E, Haites N, Van Broeckhoven C. Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies. Hum Mutat. 1999. 13(1):11-28. [Medline].

  41. Shy ME, Jáni A, Krajewski K, Grandis M, Lewis RA, Li J. Phenotypic clustering in MPZ mutations. Brain. 2004 Feb. 127(Pt 2):371-84. [Medline].

  42. Boerkoel CF, Takashima H, Garcia CA, Olney RK, Johnson J, Berry K. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol. 2002 Feb. 51(2):190-201. [Medline].

  43. Hattori N, Yamamoto M, Yoshihara T, Koike H, Nakagawa M, Yoshikawa H. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain. 2003 Jan. 126(Pt 1):134-51. [Medline].

  44. Shy ME. Peripheral neuropathies caused by mutations in the myelin protein zero. J Neurol Sci. 2006 Mar 15. 242(1-2):55-66. [Medline].

  45. Bruzzone R, White TW, Paul DL. Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem. 1996 May 15. 238(1):1-27. [Medline].

  46. Birouk N, Le Guern E, Maisonobe T, et al. X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiological study. Neurology. 1998. 50:1074-82.

  47. Hahn AF, Bolton CF, White CM, Brown WF, Tuuha SE, Tan CC. Genotype/phenotype correlations in X-linked dominant Charcot-Marie-Tooth disease. Ann N Y Acad Sci. 1999 Sep 14. 883:366-82. [Medline].

  48. Dubourg O, Tardieu S, Birouk N, Gouider R, Léger JM, Maisonobe T. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. Brain. 2001 Oct. 124(Pt 10):1958-67. [Medline].

  49. Züchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet. 2004 May. 36(5):449-51. [Medline].

  50. Koshiba T, Detmer SA, Kaiser JT, Chen H, McCaffery JM, Chan DC. Structural basis of mitochondrial tethering by mitofusin complexes. Science. 2004 Aug 6. 305(5685):858-62. [Medline].

  51. Baloh RH, Schmidt RE, Pestronk A, Milbrandt J. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations. J Neurosci. 2007 Jan 10. 27(2):422-30. [Medline].

  52. Emery AE. Population frequencies of inherited neuromuscular diseases--a world survey. Neuromuscul Disord. 1991. 1(1):19-29. [Medline].

  53. Kurihara S, Adachi Y, Wada K, Awaki E, Harada H, Nakashima K. An epidemiological genetic study of Charcot-Marie-Tooth disease in Western Japan. Neuroepidemiology. 2002 Sep-Oct. 21(5):246-50. [Medline].

  54. Ionasescu V, Searby C, Sheffield VC, Roklina T, Nishimura D, Ionasescu R. Autosomal dominant Charcot-Marie-Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet. 1996 Sep. 5(9):1373-5. [Medline].

  55. Nelis E, Van Broeckhoven C, De Jonghe P, Löfgren A, Vandenberghe A, Latour P. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet. 1996. 4(1):25-33. [Medline].

  56. Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology. 2005 Jul 26. 65(2):197-204. [Medline].

  57. Garcia CA, Malamut RE, England JD, Parry GS, Liu P, Lupski JR. Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology. 1995 Nov. 45(11):2090-3. [Medline].

  58. Marques W Jr, Hanna MG, Marques SR, Sweeney MG, Thomas PK, Wood NW. Phenotypic variation of a new P0 mutation in genetically identical twins. J Neurol. 1999 Jul. 246(7):596-9. [Medline].

  59. Pfeiffer G, Wicklein EM, Ratusinski T, Schmitt L, Kunze K. Disability and quality of life in Charcot-Marie-Tooth disease type 1. J Neurol Neurosurg Psychiatry. 2001 Apr. 70(4):548-50. [Medline].

  60. Dyck PJ, Karnes JL, Lambert EH. Longitudinal study of neuropathic deficits and nerve conduction abnormalities in hereditary motor and sensory neuropathy type 1. Neurology. 1989 Oct. 39(10):1302-8. [Medline].

  61. Killian JM, Tiwari PS, Jacobson S, Jackson RD, Lupski JR. Longitudinal studies of the duplication form of Charcot-Marie-Tooth polyneuropathy. Muscle Nerve. 1996 Jan. 19(1):74-8. [Medline].

  62. Teunissen LL, Notermans NC, Franssen H, Van Engelen BG, Baas F, Wokke JH. Disease course of Charcot-Marie-Tooth disease type 2: a 5-year follow-up study. Arch Neurol. 2003 Jun. 60(6):823-8. [Medline].

  63. Thomas FP, Geller TJ, Hahn AF, et al. Modification of CMT1A phenotypes by independent co-existing neurogenetic disorders, McArdle disease and chromosome 5p trisomy. Ann NY Acad Sci. 1999. 883:472-6.

  64. Thomas PK, Marques W Jr, Davis MB, Sweeney MG, King RH, Bradley JL, et al. The phenotypic manifestations of chromosome 17p11.2 duplication. Brain. 1997 Mar. 120 ( Pt 3):465-78. [Medline].

  65. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980 Jun. 103(2):259-80. [Medline].

  66. Harding AE, Thomas PK. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet. 1980 Oct. 17(5):329-36. [Medline].

  67. Yiu EM, Ryan MM. Genetic axonal neuropathies and neuronopathies of pre-natal and infantile onset. J Peripher Nerv Syst. 2012 Sep. 17(3):285-300. [Medline].

  68. Rosen SA, Wang H, Cornblath DR, Uematsu S, Hurko O. Compression syndromes due to hypertrophic nerve roots in hereditary motor sensory neuropathy type I. Neurology. 1989 Sep. 39(9):1173-7. [Medline].

  69. Bienfait HM, Baas F, Koelman JH, de Haan RJ, van Engelen BG, Gabreëls-Festen AA. Phenotype of Charcot-Marie-Tooth disease Type 2. Neurology. 2007 May 15. 68(20):1658-67. [Medline].

  70. Hoogendijk J. E., Hensels G. W., Gabrëels-Festen A. A., et al. De novo mutation in hereditary motor and sensory neuropathy type 1. Lancet. 1992. 339:1081-2.

  71. Berciano J, Garcia A, and Combarros O. Initial semiology in children with Charcot-Marie-Tooth disease 1A duplication. Muscle Nerve. 2003. 27:34-39.

  72. Bienfait HM, Verhamme C, van Schaik IN, et al. Comparison of CMT1A and CMT2: similarities and differences. J Neurology. 2006. 253:1572-80.

  73. Elliott JL, Kwon JM, Goodfellow PJ, Yee WC. Hereditary motor and sensory neuropathy IIB: clinical and electrodiagnostic characteristics. Neurology. 1997 Jan. 48(1):23-8. [Medline].

  74. Dyck PJ, Litchy WJ, Minnerath S, et al. Hereditary motor and sensory neuropathywith diaphragm and vocal cord paresis. Ann Neurol. 1994. 35:608-15.

  75. De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain. 1999. 122:281-290.

  76. Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology. 1993 Dec. 43(12):2558-64. [Medline].

  77. Mastaglia FL, Nowak KJ, Stell R, Phillips BA, Edmondston JE, Dorosz SM, et al. Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry. 1999 Aug. 67(2):174-9. [Medline].

  78. De Jonghe P, Mersivanova I, Nelis E, Del Favero J, Martin JJ, Van Broeckhoven C, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol. 2001 Feb. 49(2):245-9. [Medline].

  79. Senderek J, Bergmann C, Ramaekers VT, Nelis E, Bernert G, Makowski A. Mutations in the ganglioside-induced differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-Marie-Tooth neuropathy. Brain. 2003 Mar. 126(Pt 3):642-9. [Medline].

  80. Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, Dewil M. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet. 2006 Feb. 38(2):197-202. [Medline].

  81. Bennett CL, Lawson VH, Brickell KL, Isaacs K, Seltzer W, Lipe HP. Late-onset hereditary axonal neuropathies. Neurology. 2008 Jul 1. 71(1):14-20. [Medline].

  82. Hoyle JC, Isfort MC, Roggenbuck J, Arnold WD. The genetics of Charcot-Marie-Tooth disease: current trends and future implications for diagnosis and management. Appl Clin Genet. 2015. 8:235-43. [Medline].

  83. Liao JP, Waclawik AJ. Nerve root hypertrophy in CMT type 1A. Neurology. 2004 Mar 9. 62(5):783. [Medline].

  84. Martinoli C, Schenone A, Bianchi S, Mandich P, Caponetto C, Abbruzzese M. Sonography of the median nerve in Charcot-Marie-Tooth disease. AJR Am J Roentgenol. 2002 Jun. 178(6):1553-6. [Medline].

  85. Dyck PJ, Lambert EH. Lower motor and primary sensory neuron diseases with peroneal muscular atrophy. II. Neurologic, genetic, and electrophysiologic findings in various neuronal degenerations. Arch Neurol. 1968 Jun. 18(6):619-25. [Medline].

  86. Lewis RA, Sumner AJ. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology. 1982 Jun. 32(6):592-6. [Medline].

  87. Kaku DA, Parry GJ, Malamut R, Lupski JR, Garcia CA. Uniform slowing of conduction velocities in Charcot-Marie-Tooth polyneuropathy type 1. Neurology. 1993 Dec. 43(12):2664-7. [Medline].

  88. Gabreëls-Festen A, Wetering RV. Human nerve pathology caused by different mutational mechanisms of the PMP22 gene. Ann N Y Acad Sci. 1999 Sep 14. 883:336-43. [Medline].

  89. Behse F, Buchthal F. Peroneal muscular atrophy (PMA) and related disorders. II. Histological findings in sural nerves. Brain. 1977 Mar. 100 Pt 1:67-85. [Medline].

  90. Guillebastre B, Calmels P, Rougier P. Effects of muscular deficiency on postural and gait capacities in patients with Charcot-Marie-Tooth disease. J Rehabil Med. 2013 Mar 6. 45(3):314-7. [Medline].

  91. Donaghy M, Sisodiya SM, Kennett R, McDonald B, Haites N, Bell C. Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation. J Neurol Neurosurg Psychiatry. 2000 Dec. 69(6):799-805. [Medline].

  92. Watanabe M, Yamamoto N, Ohkoshi N, Nagata H, Kohno Y, Hayashi A. Corticosteroid- responsive asymmetric neuropathy with a myelin protein zero gene mutation. Neurology. 2002 Sep 10. 59(5):767-9. [Medline].

  93. Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB. Coexistent hereditary and inflammatory neuropathy. Brain. 2004 Jan. 127(Pt 1):193-202. [Medline].

  94. Kaya F, Belin S, Bourgeois P, Micaleff J, Blin O, Fontés M. Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord. 2007 Mar. 17(3):248-53. [Medline].

  95. Pareyson D, Schenone A, Fabrizi GM, Santoro L, Padua L, Quattrone A. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]. Pharmacol Res. 2006 Dec. 54(6):436-41. [Medline].

  96. Pareyson D, Reilly MM, Schenone A, et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011 Apr. 10(4):320-328. [Medline].

  97. Meyer zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol. 2007 Jan. 61(1):61-72. [Medline].

  98. Shy ME, Chen L, Swan ER, Taube R, Krajewski KM, Herrmann D, et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology. 2008 Jan 29. 70(5):378-83. [Medline].

  99. Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci. 2006 Mar 15. 242(1-2):47-54. [Medline].

  100. Antognini JF. Anaesthesia for Charcot-Marie-Tooth disease: a review of 86 cases. Can J Anaesth. 1992 Apr. 39(4):398-400. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.